Esophageal cancer secondary prevention

Jump to navigation Jump to search

Esophageal cancer Microchapters


Patient Information


Historical Perspective



Differentiating Esophageal cancer from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound



Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophageal cancer secondary prevention On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Esophageal cancer secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophageal cancer secondary prevention

CDC on Esophageal cancer secondary prevention

Esophageal cancer secondary prevention in the news

Blogs on Esophageal cancer secondary prevention

Directions to Hospitals Treating Esophageal cancer

Risk calculators and risk factors for Esophageal cancer secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]


Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.

Secondary Prevention

Secondary prevention can be effective in high risk groups with advanced dysplasia if they are treated (with monoclonal antibodies) early enough in the dysplastic phase before cancer occurs.[1]

  • A high risk group who frequently smoke and drink alcohol were identified in Hishun village, China.
  • They were examined by esophageal exfoliative cytology.
  • One third of the participants were found to have advanced esophageal dysplasia.
  • They were placed on an antitumor B regimen for 3 years.
  • Patients who were treated with monoclonal antibodies subsequently showed a reduction in the incidence of esophageal cancer by 53%.
  • These results demonstrate the effectiveness of secondary prevention in the prevention of esophageal cancer.


  1. Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP (1988). "[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]". Zhonghua Zhong Liu Za Zhi (in Chinese). 10 (3): 161–6. PMID 3219974.

Template:WikiDoc Sources